Citigroup

Citigroup moves its rating on NYSE Euronext (NYSE: NYX) to Neutral from Hold/High Risk and cuts its target price by $10 to $29 a share following a hiatus during which Citigroup could not publish anything on the company. Citigroup says, "Despite the failure to close the DB1 merger, NYX will...

Citigroup lowers its price target on Medtronic (NYSE: MDT) to $48, up $3, while reiterating its Buy rating as it trims estimates on the company, reflecting the belief that the med tech mart experienced a difficult January. Citigroup says, "We are lowering our F3Q12 sales forecast to $4.05B (+2.2...

Citigroup says it lowers its rating on Buckeye Partners (NYSE: BPL) to Sell from Buy and cuts its price target to $58, down $66, on high risks coming from high leverage and low coverage. Citigroup says, "After another quarter of disappointing operating results we are downgrading BPL to Sell and...

Citigroup resumes its Buy rating on WisdomTree Investments (NASDAQ: WETF) with a lower price target of $8 (from $9.50), reflecting revised EPS estimates, AUM growth assumptions and attendant platform risks. Citigroup says, "We are shifting from GAAP EPS to look through transitory litigation...

Citigroup lowers its rating on Estee Lauder (NYSE: EL) to Neutral from Buy and lowers its price target to $64 from $67.50 on near-term concerns on top-line and margin performance. Citigroup says, "While we still consider EL to be a high quality “buy and hold” story, we fear that during CY12, the...